Back to Journals » Drug Design, Development and Therapy » Volume 8

Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen

Authors Helmschrott M, Beckendorf J, Akyol C, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Ehlermann P, Bruckner T, Katus HA, Doesch AO

Received 29 May 2014

Accepted for publication 30 June 2014

Published 9 September 2014 Volume 2014:8 Pages 1307—1314

DOI https://doi.org/10.2147/DDDT.S68542

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Matthias Helmschrott,1 Jan Beckendorf,1 Ceylan Akyol,1 Arjang Ruhparwar,2 Bastian Schmack,2 Christian Erbel,1 Christian A Gleissner,1 Mohammadreza Akhavanpoor,1 Philipp Ehlermann,1 Tom Bruckner,3 Hugo A Katus,1 Andreas O Doesch1

1Department of Cardiology, Angiology, Pneumology, University of Heidelberg, Heidelberg, Germany; 2Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; 3Institute for Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany

Background: The use of tacrolimus (TAC) in patients after heart transplantation (HTX) has increased over the last few years.
Aim: In this retrospective study, we evaluated the effects of a TAC (conventional and extended-release TAC)-based immunosuppressive therapy regarding rejection profile in comparison to a cyclosporine A (CSA)-based regimen in patients after HTX.
Methods: The data of 233 patients who underwent HTX at the Heidelberg Heart Transplantation Center from May 1998 until November 2010 were retrospectively analyzed. Primary immunosuppressive therapy was changed from a CSA (n=114) to a TAC (n=119)-based regimen in February 2006 according to center routine. Follow-up period was 2 years post-HTX. Primary endpoint was time to first biopsy-proven rejection requiring therapy. In all patients, routine follow-up at the Heidelberg Heart Transplantation Center was mandatory.
Results: Multivariate risk factor analysis regarding time to first rejection episode showed no statistically significant differences regarding recipient age, donor age, recipient sex, donor sex, sex mismatch, ischemic time, and diagnosis leading to HTX between the two groups (all P= not statistically significant). Time to first biopsy-proven rejection was significantly longer in the TAC group (intention-to-treat analysis, n=233, log-rank test P<0.0001; per-protocol analysis, n=150, log-rank test P=0.0003). In patients who underwent a change of primary immunosuppression (n=49), a significantly longer time to first biopsy-proven rejection was also found in the primary TAC subgroup (log-rank test P=0.0297). Further subgroup analysis in the TAC subgroups showed no statistically significant differences in time to biopsy-proven rejection under extended-release TAC compared to conventional TAC (intention-to-treat analysis, log-rank test P=0.1736).
Conclusion: Our study demonstrated that a TAC-based primary immunosuppressive therapy is superior to a CSA-based immunosuppressive regimen in patients after HTX regarding time to first biopsy-proven rejection.

Keywords: extended-release tacrolimus, cyclosporine A, renal function

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Chronic digitalis therapy in patients before heart transplantation is an independent risk factor for increased posttransplant mortality

Rivinius R, Helmschrott M, Ruhparwar A, Rahm AK, Darche FF, Thomas D, Bruckner T, Ehlermann P, Katus HA, Doesch AO

Therapeutics and Clinical Risk Management 2017, 13:1399-1407

Published Date: 13 October 2017

Comparison of posttransplant outcomes in patients with no, acute, or chronic amiodarone use before heart transplantation

Rivinius R, Helmschrott M, Ruhparwar A, Darche FF, Thomas D, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2017, 11:1827-1837

Published Date: 19 June 2017

Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy

Helmschrott M, Rivinius R, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2017, 11:1673-1680

Published Date: 7 June 2017

The influence of surgical technique on early posttransplant atrial fibrillation — comparison of biatrial, bicaval, and total orthotopic heart transplantation

Rivinius R, Helmschrott M, Ruhparwar A, Erbel C, Gleissner CA, Darche FF, Thomas D, Bruckner T, Katus HA, Doesch AO

Therapeutics and Clinical Risk Management 2017, 13:287-297

Published Date: 8 March 2017

Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation

Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Schweizer PA, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2016, 10:677-686

Published Date: 16 February 2016

Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation

Helmschrott M, Rivinius R, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Ehlermann P, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2015, 9:1217-1224

Published Date: 24 February 2015

Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy

Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Klein B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2015, 9:93-102

Published Date: 17 December 2014

Inhibition of B7-1 (CD80) by RhuDex® reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions

Doesch AO, Zhao L, Gleissner CA, Akhavanpoor M, Rohde D, Okuyucu D, Hakimi M, Dengler TJ, Katus HA, Erbel C

Drug Design, Development and Therapy 2014, 8:447-457

Published Date: 12 May 2014

Conversion to generic cyclosporine A in stable chronic patients after heart transplantation

Kraeuter M, Helmschrott M, Erbel C, Gleissner CA, Frankenstein L, Schmack B, Ruhparwar A, Ehlermann P, Katus HA, Doesch AO

Drug Design, Development and Therapy 2013, 7:1421-1426

Published Date: 28 November 2013

Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study

Doesch AO, Mueller S, Erbel C, Gleissner CA, Frankenstein L, Hardt S, Ruhparwar A, Ehlermann P, Dengler T, Katus HA

Drug Design, Development and Therapy 2013, 7:1323-1328

Published Date: 5 November 2013

Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation

Doesch AO, Mueller S, Akyol C, Erbel C, Frankenstein L, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA

Drug Design, Development and Therapy 2013, 7:1253-1258

Published Date: 21 October 2013

Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation

Gueler I, Mueller S, Helmschrott M, Oeing CU, Erbel C, Frankenstein L, Gleissner C, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA, Doesch AO

Drug Design, Development and Therapy 2013, 7:297-303

Published Date: 8 April 2013

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients

Doesch AO, Repp J, Hofmann N, Erbel C, Frankenstein L, Gleissner CA, Schmidt C, Ruhparwar A, Zugck C, Schnitzler P, Ehlermann P, Dengler TJ, Katus HA

Drug Design, Development and Therapy 2012, 6:289-295

Published Date: 12 October 2012

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010